{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T23:22:50Z","timestamp":1791588170711,"version":"4.3.4"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2023,7,17]],"date-time":"2023-07-17T00:00:00Z","timestamp":1689552000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,7,17]],"date-time":"2023-07-17T00:00:00Z","timestamp":1689552000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1007\/s40262-023-01268-w","type":"journal-article","created":{"date-parts":[[2023,7,17]],"date-time":"2023-07-17T15:01:57Z","timestamp":1689606117000},"page":"1049-1061","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Clinical Pharmacokinetics and Pharmacodynamics of the Next Generation Androgen Receptor Inhibitor\u2014Darolutamide"],"prefix":"10.1007","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-4101-4353","authenticated-orcid":false,"given":"Eva","family":"Podgor\u0161ek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4794-1831","authenticated-orcid":false,"given":"Niven","family":"Mehra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8002-1869","authenticated-orcid":false,"given":"Inge M.","family":"van Oort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5277-6586","authenticated-orcid":false,"given":"Diederik M.","family":"Somford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3041-6774","authenticated-orcid":false,"given":"Emmy","family":"Boerrigter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1553-178X","authenticated-orcid":false,"given":"Nielka P.","family":"van Erp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,17]]},"reference":[{"key":"1268_CR1","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2022.811044","volume":"10","author":"L Wang","year":"2022","unstructured":"Wang L, et al. Prostate cancer incidence and mortality: global status and temporal trends in 89 countries from 2000 to 2019. Front Public Health. 2022;10: 811044.","journal-title":"Front Public Health"},{"issue":"12","key":"1268_CR2","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","volume":"34","author":"HI Scher","year":"2016","unstructured":"Scher HI, et al. Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol. 2016;34(12):1402\u201318.","journal-title":"J Clin Oncol"},{"issue":"7","key":"1268_CR3","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.3390\/cancers14071792","volume":"14","author":"C Cattrini","year":"2022","unstructured":"Cattrini C, et al. Apalutamide, Darolutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC): A Critical Review. Cancers (Basel). 2022;14(7):1792. https:\/\/doi.org\/10.3390\/cancers14071792.","journal-title":"Cancers (Basel)"},{"issue":"11","key":"1268_CR4","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1056\/NEJMoa2001342","volume":"383","author":"K Fizazi","year":"2020","unstructured":"Fizazi K, et al. Nonmetastatic, castration-resistant prostate cancer and survival with darolutamide. N Engl J Med. 2020;383(11):1040\u20139.","journal-title":"N Engl J Med"},{"issue":"13","key":"1268_CR5","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1056\/NEJMoa1815671","volume":"380","author":"K Fizazi","year":"2019","unstructured":"Fizazi K, et al. Darolutamide in nonmetastatic, castration-resistant prostate cancer. N Engl J Med. 2019;380(13):1235\u201346.","journal-title":"N Engl J Med"},{"key":"1268_CR6","unstructured":"Dawson NA, Leger P. Overview of the treatment of castration-resistant prostate cancer (CRPC). 2022 15.12.2022]; https:\/\/www.uptodate.com\/contents\/overview-of-the-treatment-of-castration-resistant-prostate-cancer-crpc. Accessed 15 Dec 2022."},{"issue":"6","key":"1268_CR7","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1007\/s00280-017-3417-3","volume":"80","author":"N Matsubara","year":"2017","unstructured":"Matsubara N, et al. Phase 1 study of darolutamide (ODM-201): a new-generation androgen receptor antagonist, in Japanese patients with metastatic castration-resistant prostate cancer. Cancer Chemother Pharmacol. 2017;80(6):1063\u201372.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1268_CR8","volume-title":"Product information: Nubeqa (darolutamide)","author":"EMA","year":"2022","unstructured":"EMA. Product information: Nubeqa (darolutamide). Amsterdam: EMA; 2022."},{"key":"1268_CR9","volume-title":"Multi-Discipline Review: Nubeqa (darolutamide)","author":"FDA","year":"2018","unstructured":"FDA. Multi-Discipline Review: Nubeqa (darolutamide). Silver Spring: FDA; 2018."},{"key":"1268_CR10","volume-title":"European Public Assesment Report (EPAR): Nubeqa (darolutamide)","author":"EMA","year":"2020","unstructured":"EMA. European Public Assesment Report (EPAR): Nubeqa (darolutamide). Amsterdam: EMA; 2020."},{"key":"1268_CR11","volume-title":"Prescribing information: Nubeqa (darolutamide)","author":"FDA","year":"2022","unstructured":"FDA. Prescribing information: Nubeqa (darolutamide). Silver Spring: FDA; 2022."},{"key":"1268_CR12","volume-title":"European Public Assessment Report (EPAR) Erleada (apalutamide)","author":"EMA","year":"2019","unstructured":"EMA. European Public Assessment Report (EPAR) Erleada (apalutamide). EMA; 2019."},{"key":"1268_CR13","volume-title":"European Public Assessment Report (EPAR) Xtandi (enzalutamide)","author":"EMA","year":"2013","unstructured":"EMA. European Public Assessment Report (EPAR) Xtandi (enzalutamide). EMA; 2013."},{"issue":"10","key":"1268_CR14","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/S1470-2045(12)70379-0","volume":"13","author":"K Fizazi","year":"2012","unstructured":"Fizazi K, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2012;13(10):983\u201392.","journal-title":"Lancet Oncol"},{"key":"1268_CR15","volume-title":"European Public Assessment Report (EPAR) Zytiga (abiraterone acetate)","author":"EMA","year":"2011","unstructured":"EMA. European Public Assessment Report (EPAR) Zytiga (abiraterone acetate). EMA; 2011."},{"issue":"26","key":"1268_CR16","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1056\/NEJMoa1800536","volume":"378","author":"M Hussain","year":"2018","unstructured":"Hussain M, et al. Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. N Engl J Med. 2018;378(26):2465\u201374.","journal-title":"N Engl J Med"},{"issue":"15","key":"1268_CR17","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1056\/NEJMoa1715546","volume":"378","author":"MR Smith","year":"2018","unstructured":"Smith MR, et al. Apalutamide treatment and metastasis-free survival in prostate cancer. N Engl J Med. 2018;378(15):1408\u201318.","journal-title":"N Engl J Med"},{"issue":"5","key":"1268_CR18","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1056\/NEJMoa1405095","volume":"371","author":"TM Beer","year":"2014","unstructured":"Beer TM, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371(5):424\u201333.","journal-title":"N Engl J Med"},{"issue":"13","key":"1268_CR19","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","volume":"367","author":"HI Scher","year":"2012","unstructured":"Scher HI, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367(13):1187\u201397.","journal-title":"N Engl J Med"},{"issue":"21","key":"1268_CR20","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","volume":"364","author":"JS de Bono","year":"2011","unstructured":"de Bono JS, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364(21):1995\u20132005.","journal-title":"N Engl J Med"},{"issue":"2","key":"1268_CR21","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1056\/NEJMoa1209096","volume":"368","author":"CJ Ryan","year":"2013","unstructured":"Ryan CJ, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013;368(2):138\u201348.","journal-title":"N Engl J Med"},{"issue":"12","key":"1268_CR22","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","volume":"386","author":"MR Smith","year":"2022","unstructured":"Smith MR, et al. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. N Engl J Med. 2022;386(12):1132\u201342.","journal-title":"N Engl J Med"},{"key":"1268_CR23","doi-asserted-by":"crossref","unstructured":"Davis ID, et al. Enzalutamide with standard first-line therapy in metastatic prostate cancer. N Engl J Med. 2019;381(2):121\u201331.","DOI":"10.1056\/NEJMoa1903835"},{"issue":"20","key":"1268_CR24","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1200\/JCO.20.03488","volume":"39","author":"KN Chi","year":"2021","unstructured":"Chi KN, et al. Apalutamide in patients with metastatic castration-sensitive prostate cancer: final survival analysis of the randomized, double-blind, phase III TITAN study. J Clin Oncol. 2021;39(20):2294\u2013303.","journal-title":"J Clin Oncol"},{"issue":"10336","key":"1268_CR25","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","volume":"399","author":"K Fizazi","year":"2022","unstructured":"Fizazi K, et al. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 x 2 factorial design. Lancet. 2022;399(10336):1695\u2013707.","journal-title":"Lancet"},{"key":"1268_CR26","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1007\/s40262-016-0403-6","volume":"55","author":"GE Benoist","year":"2016","unstructured":"Benoist GE, et al. Pharmacokinetic aspects of the two novel oral drugs used for metastatic castration-resistant prostate cancer: abiraterone acetate and enzalutamide. Clin Pharmacokinet. 2016;55(11):1369\u201380.","journal-title":"Clin Pharmacokinet"},{"key":"1268_CR27","volume-title":"Prescribing information: Zytiga (abiraterone acetate)","author":"FDA","year":"2021","unstructured":"FDA. Prescribing information: Zytiga (abiraterone acetate). Silver Spring: FDA; 2021."},{"key":"1268_CR28","volume-title":"Product information: Zytiga (abiraterone acetate)","author":"EMA","year":"2022","unstructured":"EMA. Product information: Zytiga (abiraterone acetate). Amsterdam: EMA; 2022."},{"key":"1268_CR29","volume-title":"Product Information: Xtandi (enzalutamide)","author":"EMA","year":"2022","unstructured":"EMA. Product Information: Xtandi (enzalutamide). Amsterdam: EMA; 2022."},{"key":"1268_CR30","volume-title":"Product information Erleada: (apalutamide)","author":"EMA","year":"2022","unstructured":"EMA. Product information Erleada: (apalutamide). Amsterdam: EMA; 2022."},{"issue":"4","key":"1268_CR31","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s40262-021-01078-y","volume":"61","author":"C Zurth","year":"2022","unstructured":"Zurth C, et al. Clinical pharmacokinetics of the androgen receptor inhibitor darolutamide in healthy subjects and patients with hepatic or renal impairment. Clin Pharmacokinet. 2022;61(4):565\u201375.","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"1268_CR32","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1007\/s00280-017-3433-3","volume":"80","author":"N Matsubara","year":"2017","unstructured":"Matsubara N, et al. Erratum to: Phase 1 study of darolutamide (ODM-201), a new-generation androgen receptor antagonist, in Japanese patients with metastatic castration-resistant prostate cancer. Cancer Chemother Pharmacol. 2017;80(6):1073\u20137.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1268_CR33","unstructured":"Compound Summary Darolutamide. 5.9.2023]; https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Darolutamide. Accessed 5 Sept 2022."},{"issue":"9","key":"1268_CR34","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/S1470-2045(14)70240-2","volume":"15","author":"K Fizazi","year":"2014","unstructured":"Fizazi K, et al. Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial. Lancet Oncol. 2014;15(9):975\u201385.","journal-title":"Lancet Oncol"},{"issue":"5","key":"1268_CR35","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/j.eururo.2015.09.046","volume":"69","author":"C Massard","year":"2016","unstructured":"Massard C, et al. Pharmacokinetics, antitumor activity, and safety of ODM-201 in patients with chemotherapy-naive metastatic castration-resistant prostate cancer: an open-label phase 1 study. Eur Urol. 2016;69(5):834\u201340.","journal-title":"Eur Urol"},{"key":"1268_CR36","doi-asserted-by":"publisher","first-page":"12007","DOI":"10.1038\/srep12007","volume":"5","author":"AM Moilanen","year":"2015","unstructured":"Moilanen AM, et al. Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies. Sci Rep. 2015;5:12007.","journal-title":"Sci Rep"},{"issue":"8","key":"1268_CR37","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1080\/00498254.2020.1723038","volume":"50","author":"P Taavitsainen","year":"2020","unstructured":"Taavitsainen P, et al. Absorption, distribution, metabolism and excretion of darolutamide (a novel non-steroidal androgen receptor antagonist) in rats. Xenobiotica. 2020;50(8):967\u201379.","journal-title":"Xenobiotica"},{"issue":"6","key":"1268_CR38","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1124\/dmd.120.000309","volume":"49","author":"P Taavitsainen","year":"2021","unstructured":"Taavitsainen P, et al. Metabolism and mass balance of the novel nonsteroidal androgen receptor inhibitor darolutamide in humans. Drug Metab Dispos. 2021;49(6):420\u201333.","journal-title":"Drug Metab Dispos"},{"issue":"6","key":"1268_CR39","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1007\/s13318-019-00577-5","volume":"44","author":"C Zurth","year":"2019","unstructured":"Zurth C, et al. Drug-drug interaction potential of darolutamide: in vitro and clinical studies. Eur J Drug Metab Pharmacokinet. 2019;44(6):747\u201359.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"6","key":"1268_CR40","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/j.euf.2017.01.010","volume":"3","author":"K Fizazi","year":"2017","unstructured":"Fizazi K, et al. Safety and antitumour activity of ODM-201 (BAY-1841788) in castration-resistant, CYP17 Inhibitor-naive prostate cancer: results from extended follow-up of the ARADES Trial. Eur Urol Focus. 2017;3(6):606\u201314.","journal-title":"Eur Urol Focus"},{"issue":"4","key":"1268_CR41","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.euf.2017.01.015","volume":"4","author":"ND Shore","year":"2018","unstructured":"Shore ND, et al. Safety and antitumour activity of ODM-201 (BAY-1841788) in chemotherapy-naive and CYP17 Inhibitor-naive patients: follow-up from the ARADES and ARAFOR Trials. Eur Urol Focus. 2018;4(4):547\u201353.","journal-title":"Eur Urol Focus"},{"key":"1268_CR42","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1111\/bcp.15057","volume":"88","author":"E Boerrigter","year":"2021","unstructured":"Boerrigter E, et al. The effect of chemotherapy on the exposure-response relation of abiraterone in metastatic castration-resistant prostate cancer. Br J Clin Pharmacol. 2022;88(3):1170\u201378.","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"1268_CR43","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1124\/pr.113.007518","volume":"65","author":"J Konig","year":"2013","unstructured":"Konig J, Muller F, Fromm MF. Transporters and drug-drug interactions: important determinants of drug disposition and effects. Pharmacol Rev. 2013;65(3):944\u201366.","journal-title":"Pharmacol Rev"},{"issue":"5","key":"1268_CR44","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s11523-019-00674-0","volume":"14","author":"N Shore","year":"2019","unstructured":"Shore N, et al. Evaluation of Clinically relevant drug-drug interactions and population pharmacokinetics of darolutamide in patients with nonmetastatic castration-resistant prostate cancer: results of pre-specified and post hoc analyses of the phase III ARAMIS Trial. Target Oncol. 2019;14(5):527\u201339.","journal-title":"Target Oncol"},{"issue":"10","key":"1268_CR45","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1007\/s40262-022-01159-6","volume":"61","author":"SAJ Buck","year":"2022","unstructured":"Buck SAJ, et al. Influence of darolutamide on cabazitaxel systemic exposure. Clin Pharmacokinet. 2022;61(10):1471\u20133.","journal-title":"Clin Pharmacokinet"},{"issue":"10","key":"1268_CR46","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.3390\/pharmaceutics14102101","volume":"14","author":"DS Sutaria","year":"2022","unstructured":"Sutaria DS, et al. Drug-drug interaction study to evaluate the pharmacokinetics, safety, and tolerability of ipatasertib in combination with darolutamide in patients with advanced prostate cancer. Pharmaceutics. 2022;14(10):2101. https:\/\/doi.org\/10.3390\/pharmaceutics1410210","journal-title":"Pharmaceutics"},{"issue":"6_suppl","key":"1268_CR47","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1200\/JCO.2023.41.6_suppl.148","volume":"41","author":"A Rezazadeh","year":"2023","unstructured":"Rezazadeh A, et al. Dosing, safety, and pharmacokinetics (PK) of combination therapy with darolutamide (DARO), androgen-deprivation therapy (ADT), and docetaxel (DOC) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) in the ARASENS study. J Clin Oncol. 2023;41(6_suppl):148\u2013148.","journal-title":"J Clin Oncol"},{"issue":"9","key":"1268_CR48","doi-asserted-by":"publisher","first-page":"e406","DOI":"10.1016\/S1470-2045(22)00221-2","volume":"23","author":"EL Giraud","year":"2022","unstructured":"Giraud EL, et al. The QT interval prolongation potential of anticancer and supportive drugs: a comprehensive overview. Lancet Oncol. 2022;23(9):e406\u201315.","journal-title":"Lancet Oncol"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-023-01268-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-023-01268-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-023-01268-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,29]],"date-time":"2023-07-29T18:07:43Z","timestamp":1690654063000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-023-01268-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,17]]},"references-count":48,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["1268"],"URL":"https:\/\/doi.org\/10.1007\/s40262-023-01268-w","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,17]]},"assertion":[{"value":"23 May 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No sources of funding were used to assist in the preparation of this review.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Eva Podgor\u0161ek, Niven Mehra, Emmy Boerrigter, Inge M van Oort, Diederik M. Somford and Nielka P. van Erp have no conflicts of interest that are directly relevant to the content of this review. Niven Mehra has attended advisory boards of MSD Oncology, Janssen-Cilag, Astellas and AstraZeneca, received travel compensation from Astellas, Roche, Bristol-Myers Squibb, MSD Oncology and Janssen-Cilag and received research funding from Pfizer, Janssen-Cilag, Astellas, Sanofi, Roche and AstraZeneca. Inge M. van Oort has attended advisory boards for Astellas, Janssen-Cilag, Bayer and MSD, has received speaker fees from Bayer, research funding from Astellas, Janssen-Cilag and Bayer and travel compensation from Astellas and Bayer. Diederik M. Somford has attended advisory boards for Astellas, Janssen-Cilag and Bayer and has received speaker fees from Bayer and research funding from Astellas, Janssen-Cilag and Bayer. Nielka P. van Erp has received research funding from Astellas and Ipsen.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Data sharing not applicable to this article as no datasets were generated or analyzed during the current study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Eva Podgor\u0161ek, Emmy Boerrigter, and Nielka van Erp were involved in the obtaining, analysis and\/or interpretation of data. Eva Podgor\u0161ek was involved in the drafting of the manuscript. Niven Mehra, Inge M. van Oort, Diederik M. Somford, Emmy Boerrigter, and Nielka P. van Erp were involved in critical revisions of the manuscript for important intellectual content. All authors were involved in the approval of the final version.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors Contributions"}}]}}